A Phase 1 Study of LY2606368 in Japanese Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 25 May 2017
At a glance
- Drugs Prexasertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly
- 19 May 2017 Status changed from active, no longer recruiting to completed.
- 08 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 01 Feb 2017 Planned End Date changed from 1 Jan 2018 to 6 Jun 2017.